As CGTs scale from clinical to commercial, Cencora's Krystal Haynes discusses the supply chain decisions that determine whether a launch succeeds.
Krystal Haynes
Advertisement
Krystal Haynes is senior director, international 3PL business development, at Cencora.
Articles by Krystal Haynes
Sponsored
Krystal Haynes, Senior Director of Business Development, ICS, at Cencora, outlines the challenges facing cell and gene therapy manufacturers as they attempt to move products from clinical development to commercial availability.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
The Hidden Architecture of Drug Shortages: Why Inventory Economics Determine Patient Access
2
Gerren McHam: What Effective Pharma Reshoring Actually Requires
3
How China Turned US Trade Compliance Into a Supply Chain Risk
4
Access by Design: Market Access Thinking Across the Drug Development Lifecycle
5